Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Net Cash Flow (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Net Cash Flow for 9 consecutive years, with -$7.1 million as the latest value for Q4 2024.

  • Quarterly Net Cash Flow fell 396.53% to -$7.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Dec 2024, up 193.89% year-over-year, with the annual reading at $57.9 million for FY2025, 409.83% up from the prior year.
  • Net Cash Flow for Q4 2024 was -$7.1 million at SELLAS Life Sciences, down from $11.9 million in the prior quarter.
  • The five-year high for Net Cash Flow was $27.1 million in Q4 2020, with the low at -$9.8 million in Q3 2023.
  • Average Net Cash Flow over 5 years is $680450.0, with a median of -$3.5 million recorded in 2020.
  • The sharpest move saw Net Cash Flow tumbled 1268.93% in 2021, then soared 814.81% in 2022.
  • Over 5 years, Net Cash Flow stood at $27.1 million in 2020, then tumbled by 118.18% to -$4.9 million in 2021, then increased by 14.27% to -$4.2 million in 2022, then surged by 65.92% to -$1.4 million in 2023, then crashed by 396.53% to -$7.1 million in 2024.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$7.1 million, $11.9 million, and -$9.3 million for Q4 2024, Q3 2024, and Q2 2024 respectively.